Prolato Clinical Research Center

IgA Nephropathy Clinical Trial: VISIONARY Trial (Sibeprenlimab) Donate to support our mission today: https://www.kidney.org/support?youtube Subscribe to our YouTube channel: http://bit.ly/nkfyoutube Learn about kidney hea...

Please take a moment to view this brief video on our clinical trial research subject.

IgA Nephropathy Clinical Trial: VISIONARY Trial (Sibeprenlimab) Donate to support our mission today: https://www.kidney.org/support?youtube Subscribe to our YouTube channel: http://bit.ly/nkfyoutube Learn about kidney hea...

Join us at Journey to Better Health and learn about clinical trials.

Journey to Better Health | AWARE for All-Houston Free health event where you learn what clinical trials are, receive free health screenings, meet organizations from your community and more!

Join Our Flu Vaccine Study Help Advance Research

Pfizer, BioNTech Find Updated COVID Booster Protects Against Omicron in Trial Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans.

Flu Season Is Starting Early and May Be Severe, Experts Warn "I'm concerned that we will have a very substantial influenza season coming up this year, very different from our two previous seasons."

Know someone who may apply? The VISIONARY Study is testing an investigational drug which aims to target the root cause of IgAN and manage the symptoms of the disease.

https://alportsyndrome.org/for-patients/clinical-trials/current-past-clinical-trials/

Clinical Trials | Alport Syndrome Foundation Clinical trials are important because they provide new insight into diseases and new treatment options. Following completion of a clinical trial, researchers evaluate the data collected and determine its value for additional research and treatment. Further clinical trials may or may not be deemed ap...

https://www.iganclinicaltrial.com/en-us/index.html

Novartis - IgAN Novartis - IgAN

https://forpatients.roche.com/en/trials/autoimmune-disorder/sle/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-62318.html

A clinical trial to look at how well obinutuzumab works to reduce certain features of systemic lupus erythematosus (SLE) when compared to placebo Use our trial search to find descriptions of clinical trials, participating trial clinics, their recruitment status and results.

Prolato Clinical Research Center is looking for a nurse practitioner for our growing clinical trial site in Houston. If you are interested, please message us at

Contact Us Contact us Please send all inquires to:[email protected](832) 338-9118 Name * First Name Last Name Email * Message * Thank you for your message. We will be in touch shortly.

PBC itch can dominate daily life so much that it feels like a disease in its own right. The GLISTEN trial assesses an investigational medication for itch related to PBC. Find out how to apply today:
https://www.glistentrial.com/us-en

If you or a loved one are affected with kidney disease, you may benefit from participating in a clinical trials. Check out our website for list of studies at

Prolato Research Bringing the best treatments to the most people where they live. Supporting healthcare and innovation. We help bring new innovative and effective treatments to the world using our network of physicians. We are based in Houston, Texas, the most diverse city in the world, and are proud to offer thes....

Check out this new video for the ARTEMIS trial, seeking to help those with IGAN

https://www.prolatoresearch.com/news/check-out-this-new-video-about-artemis-for-patients-with-igan

The National Institute of Health has a great page on why you might want to consider participating in a clinical trial. Check it out and if you have more questions, reach out to one of our coordinators at contact us at [email protected] or visit our site a www.prolatoresearch.com https://www.nia.nih.gov/health/what-are-clinical-trials-and-studies

What Are Clinical Trials and Studies? Interested in clinical research? Learn about the phases of clinical trials, why older and diverse participants are needed, and what to ask before participating.

If you or someone you know has Lupus, you could be eligible for a clinical trial. A trial might be right for you if your treatment isn't working as you'd like, you are struggling to pay for medication, or you want to help other patients by proving a new therapy. if interested, visit our site https://www.prolatoresearch.com/lupus

Know your risk, as a patient with SLE Lupus a new study finds that you are more likely to have heart disease

https://www.lupusresearch.org/people-with-lupus-and-especially-lupus-nephritis-at-higher-risk-for-heart-disease-study-shows/

People with Lupus and Especially Lupus Nephritis at Higher Risk for Heart Disease, Study Shows - Lupus Research People with SLE are at risk for cardiovascular diseases, and those with lupus nephritis are at greater risk, shows new analysis.

Membranous Nephropathy

Many diseases can affect your kidney function by attacking and damaging the glomeruli, the tiny filtering units inside your kidney where blood is cleaned. Glomerular diseases include many conditions with many different genetic and environmental causes. Membranous nephropathy (MN) is a type of glomerular disease and is an autoimmune disease. An autoimmune disease is caused when your body’s defense system turns against you and harms your body when it should be protecting you. Your defense system is known as your immune system which is “turned on” by glomerular disease. MN is one of the most common causes of nephrotic syndrome. When your immune system attacks the glomeruli in membranous nephropathy, it causes changes to the filters that lead you to lose large amount of protein into the urine. If this continues at high levels, it can eventually lead to kidney failure.

We recommend speaking to your primary care physician before enrolling in any trial, and if you have further questions or concerns, feel free to send us a message here. We look forward to having you on our team, as you help us to help you and others! To see available trials please visit us at www.prolatoresearch.com/membranous-nephropathy

Immunoglobulin A Nephropathy (IgAN )

IgAN is an abbreviation for Immunoglobulin A Nephropathy and is also known as Berger’s disease. It is a critical progressive, autoimmune condition that results in the glomeruli inside the kidneys becoming damaged and inflamed. After some time, the inflammation can adversely affect the kidneys’ ability to filter waste from the blood, leading to kidney disease if not correctly and promptly treated.

Immunoglobulin A nephropathy reduces the glomerular filtration rate (how the kidneys filter wastes from the blood) and causes large amounts of protein to enter the urine. The protein makes the urine appear foamy. This condition affects between 130,000–150,000 people in the United States, and its causes are still not completely understood.

Purpose Of Our Trial

It is our aim to help persons affected by IgAN to receive effective treatments, and as such, this trial is intended to evaluate the potential benefit of sparsentan on kidney function. We will take an in-depth look at how it affects protein in urine and changes the estimated glomerular filtration rate (eGFR) compared to the current standard treatment.

Benefit Of Our Trial

Unfortunately, up to 50% of persons diagnosed with IgAN progress to end-stage kidney disease within the period of ten to twenty years, and some in less. Treating this condition requires a lot of time and financial resources since dialysis and kidney transplants are necessary after some time.
These strenuous cost burdens, coupled with the fact that no cure currently exists for IgA nephropathy, are a few reasons why participating in trials such as these are beneficial. Understanding how sparsentan works against IgAN can save time, money, energy, and lives.

Being A Part Of Our Trial

To become a volunteer in our trial, you must be an adult, 18 years or older, with a biopsy-proven diagnosis of primary IgAN. To view the other requirements for your participation, please visit the site.

IgAN is a chronic condition and can affect anyone at any stage of their life. We want to help by providing an efficient, convenient, and affordable solution. Don’t you want to help
We recommend speaking to your primary care physician before enrolling in any trial, and if you have further questions or concerns, feel free to send us a message here. We look forward to having you on our team, as you help us to help you and others!
To see available trials please visit us at
https://www.prolatoresearch.com/igan

FSGS

Focal segmental glomerulosclerosis (FSGS) is a condition affecting the glomeruli, which is the area within the kidney that removes waste matter from the blood. In FSGS, scar tissue develops on the glomeruli and may be a complication of several other conditions, such as obesity, diabetes, other kidney diseases, and sickle cell. FSGS ought not to be taken lightly, as it can cause kidney failure, an even more serious condition for which treatment is either dialysis or kidney transplant. There are three types of FSGS; primary, secondary, and genetic.



Did you know that approximately 40% of adults and 20% of children with nephrotic syndrome are affected by FSGS? In fact, within the United States alone, FSGS accounts for 5%-20% of all people affected by end-stage renal disease. So chances are you may know someone who, unfortunately, is affected by FSGS.


Benefit Of Our Trial
Treating FSGS is typically a lengthy and costly process involving numerous specialists. Our Phase 2 trial, which lasts for a period of 12 weeks, aims to provide another management option that will simplify the treatment process for patients and healthcare providers.


Purpose Of Our Trial
This step in our journey of helping FSGS patients is geared at evaluating the efficacy, safety, tolerability, and pharmacokinetics of PF-06730512. After receiving the medication, our adult volunteers will be assessed to determine how the drug moves through the body, its effectiveness, possible side effects, etc.



You Or Your Loved One Can Be A Part Of Our Trial
To become a volunteer in our trial, you must at least be an adult, 18 years or older, with a confirmed diagnosis of FSGS. To view the other requirements for your participation, click here. Please note that even though you may be diagnosed with FSGS, you may not be approved for this trial if you:

are diagnosed with collapsing FSGS.
have advanced chronic changes on renal biopsy as evidenced by greater than 50% tubulointerstitial fibrosis.
have a body mass index (BMI) greater than 45 kg/m2.



In so many cases, the treatment administered to FSGS and other conditions is inefficient; and it is with being a part of a trial that patients actually find management that makes a difference and sometimes is life-saving. Also, playing a role in an initiative that could potentially help millions of people to live a better life is one of the most fulfilling and motivating feelings to experience. We recommend speaking to your primary care physician before enrolling in any trial, and if you have further questions or concerns, feel free to send us a message here. We look forward to having you on our team, as you help us to help you and others! To see available trials, please visit us https://www.prolatoresearch.com/fsgs

FSGS — Prolato FSGS Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental glomerulosclerosis is a type of glomerular disease and describes scarring (sclerosis) in your kidney. The scarring of FSGS only takes place in small sections of each glomerulus (filter), and only a limited number of glomeruli are damaged....

Diabetic Nephropathy
In the United States, about 100 million Americans are diabetics. There’s always a relationship between diabetes and kidney diseases. How is this so? Due to diabetes, the small blood vessels in the body are injured, leaving the kidney unable to purify your kidney.
Simply put, your kidney is doing its job at a poor level, or not even doing it at all. You have a build-up of waste in your body, spilling the waste and damaging other organs.

Why Are We Doing This Trial
With the current study under GFB-887-201, we hope to assess the safety and tolerability of the drug not only for patients of diabetic nephropathy, but also with focal segment glomerulosclerosis, and treatment-resistant minimal change diseases.
Across the United States, we’ll be bringing on board 125 people for this trial. We’ll be randomizing the participants to receive 3 ascending doses or a placebo.

Who Is Eligible For This Trial
To know your eligibility status for this trial, please click on this link; https://www.prolatoresearch.com/gfb887201. However, we are excluding patients with other forms of kidney disease other than DN, FSGS, and TR-MCD. Other exclusions include;
Any patient with a body mass above 40kg
With a history of malignancy,
History of organ transplants or kidney grafts,
Any history of drug, alcohol, and chemical abuse,
Any DN patients with a renal disease requiring immunosuppressive therapy,
In FSGS/TR-MCD patients, Currently on calcineurin inhibitors or history of resistance to calcineurin inhibitors, or Known history of severe or chronic hepatobiliary disease.

Final Thoughts
If you are battling with DN, FSGS, or TR-MCD, just know that you are not alone. You are part of the reasons why we are hoping that this trial will bring positive results to alleviate the pains about 1 in every 3 Americans are going through. This will require the full cooperation of our participants with our specialists.
Questions, suggestion, or concerns, please reach out via https://www.prolatoresearch.com/contact-us

Diabetes — Prolato DIABETES Type II DiabetesDiabetes is a condition in which your body has trouble controlling the level of sugar (glucose) in your blood. Insulin is a hormone that regulates the amount of sugar in your blood. With diabetes, your body either does not make enough insulin or cannot use the insulin your b...